RxDoctor Payments Data

Paramvir Rahal, MD

Gastroenterology · Bakersfield, CANPI 1003893223

Payments from drug & device makers

$4,024in general payments, 2019–2025

Across 283 payments — averaging $14.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$965
  • Aimmune Therapeutics, Inc.$686
  • Bristol Myers Squibb$307
  • Nestle Healthcare Nutrition Inc.$274
  • Gilead$267
  • Johnson & Johnson$216
  • plus $1K from 18 others

What the payments were for

  • Consulting fees$231%
  • Food & beverage$4,00199%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,024 in reported general payments places this provider in the 60th percentile of 1,885 gastroenterology providers in California.

See all gastroenterology providers in California

Medicare billing

Part B allowed, 2024
$347,855
Medicare patients
1,216
Services billed
3,702

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide455$224,737
ZenpepLipase/Protease/Amylase35$113,267
CreonLipase/Protease/Amylase25$67,069
XifaxanRifaximin16$51,773
VemlidyTenofovir Alafenamide15$26,108
IbsrelaTenapanor Hcl13$22,534
Dexlansoprazole DrDexlansoprazole48$10,661
TrulancePlecanatide17$10,295
Omeprazole1,347$9,304
Pantoprazole Sodium1,059$9,095
Hydrocortisone136$3,904
Lactulose35$2,050
Dicyclomine Hcl302$1,856
Procto-Med HcHydrocortisone126$1,751
Famotidine269$1,664

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$965$291,806480 claims
Aimmune Therapeutics, Inc.Zenpep$686$113,26735 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Trulance$195$62,06933 claims
GileadVemlidy$267$26,10815 claims
Ardelyx, Inc.Ibsrela$202$22,53413 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,885 gastroenterology providers in California.

Other gastroenterology in Bakersfield

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →